Veeda Clinical Unlisted Shares
₹ 460
Veeda Clinical Unlisted Shares Prices
Veeda Clinical Unlisted Shares
Invest Now
Veeda Clinical Unlisted Shares Business
Veeda Clinical Research (now Veeda Lifesciences) is an Indian company that helps develop new medicines by running tests and clinical trials. Started in 2004 and based in Ahmedabad, it works worldwide, including in Europe and North America. They offer services like early-stage drug testing, clinical trials, and safety monitoring. Veeda uses advanced technology to make trials faster and more accurate. They are strong in cancer research and have grown by acquiring other companies to expand their expertise. Veeda helps make sure new medicines are safe and effective before they reach patients.
Veeda Clinical Unlisted Shares Key Ratios
Veeda Clinical Unlisted Shares Financials
(Rs. in crores)
| Particulars | Mar-24 | Mar-25 |
|---|---|---|
| Net Revenue | 388.78 | 609.73 |
| Other Income | 19.21 | 11.41 |
| Total Income | 407.99 | 621.14 |
| Operating Expenses | 38.20 | 40.54 |
| Employee Expenses | 126.44 | 220.99 |
| Depreciation | 53.36 | 147.71 |
| Finance Costs | 14.60 | 54.27 |
| Clinical and Research Exp | 73.93 | 96.80 |
| Other Expenses | 98.21 | 126.39 |
| Total Expenses | 404.73 | 686.69 |
| Profit Before Tax | 3.26 | -65.55 |
| Income Tax | 3.62 | 1.26 |
| Profit After Tax | -0.36 | -66.81 |
| OCI | 0.79 | 8.44 |
| Profit for the Period | 0.43 | -58.38 |
(Rs. in crores)
| Particulars | Mar-24 | Mar-25 |
|---|---|---|
| Fixed Assets | 1,386.95 | 1,310.72 |
| CWIP | 33.20 | 24.87 |
| Investments | 79.23 | 40.77 |
| Trade Receivables | 120.90 | 77.13 |
| Other Assets | 419.93 | 409.76 |
| Total Assets | 2,040.21 | 1,863.24 |
| Share Capital | 12.60 | 13.16 |
| Reserves | 1,047.37 | 842.60 |
| Borrowings | 261.69 | 405.97 |
| Trade Payables | 65.48 | 47.60 |
| Other Liablities | 653.07 | 553.91 |
| Total Liablities | 2,040.21 | 1,863.24 |
(Rs. in crores)
| Particulars | Mar-24 | Mar-25 | A |
|---|---|---|---|
| Cashflow from Operating Activities | 58.89 | 33.32 | |
| Cashflow from Investing Activities | -446.91 | -149.31 | |
| Cashflow from Financing Activities | 399.65 | 91.41 |
Veeda Clinical Unlisted Shares Management
| Name | Designation |
|---|---|
| Mahesh Bhalgat | Managing Director |
| Nitin Deshmukh | Chairman |
Veeda Clinical Unlisted Shares Documents
Veeda Clinical Unlisted Shares News
Veeda Clinical and Shringar House of Mangalsutra gets SEBI nod
09 Jul 2025Frequently Asked questions?
Find answers to common questions that come in your mind related to IPO.
Click the “Invest Now” button and place your bids through WhatsApp. Our process experts will guide you through the entire transaction.
Once the transaction is completed, your Veeda Clinical Unlisted Shares will appear in your Depository account (CDSL or NSDL)
To sell your shares, please contact our team for the latest resale options and guidance.
The indicative price of Veeda Clinical Unlisted Shares is ₹ 460 per share as of today.
The indicative price of Veeda Clinical Unlisted Shares is ₹ 460 per share as of today.
The minimum lot size for Veeda Clinical Unlisted Shares is 100 shares when investing with IPO360
CML Copy, PAN Card, Aadhar Card and Cancelled Cheque
There are no additional charges other than its Price per share. Stamp duty, DP charges, and brokerage are borne by us, making the transaction all-inclusive.
Subject to the availability of inventory, Veeda Clinical Unlisted Shares shares are usually credited to your account within 1-2 working days.
Shares of Veeda Clinical Unlisted Shares are locked in for 6 months from the IPO allotment date.
The listing timeline depends on the discretion of the company's management and shareholders.
Veeda Clinical Research Limited (Veeda Clinical) is a specialized global Contract Research Organization (CRO) that has recently undergone a major brand and business transformation. Operating at the intersection of life sciences, technology, and advanced clinical methodologies, the Group is focused on delivering end-to-end drug development solutions to pharmaceutical and biotechnology innovators worldwide.